LEADER 04849nam 2200661 450 001 9910131339603321 005 20200520144314.0 010 $a1-118-89256-9 010 $a1-118-89255-0 010 $a1-118-89257-7 035 $a(CKB)3710000000374806 035 $a(EBL)1964101 035 $a(SSID)ssj0001456758 035 $a(PQKBManifestationID)12620708 035 $a(PQKBTitleCode)TC0001456758 035 $a(PQKBWorkID)11435409 035 $a(PQKB)11158382 035 $a(PQKBManifestationID)16036445 035 $a(PQKB)24869438 035 $a(MiAaPQ)EBC1964101 035 $a(DLC) 2015014108 035 $a(Au-PeEL)EBL1964101 035 $a(CaPaEBR)ebr11032414 035 $a(CaONFJC)MIL770051 035 $a(OCoLC)904959309 035 $a(PPN)200131869 035 $a(EXLCZ)993710000000374806 100 $a20150331h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntineoplastic drugs $eorganic synthesis /$fDaniel Lednicer 210 1$aChichester, England :$cWiley,$d2015. 210 4$dİ2015 215 $a1 online resource (230 p.) 300 $aDescription based upon print version of record. 311 $a1-118-89254-2 320 $aIncludes bibliographical references at the end of each chapters and indexes. 327 $aTitle Page; Copyright Page; Contents; Preface; Introduction; Chapter 1 Alkylating Agents; 1.1 bis-Chloroethyl Amines; 1.2 Several Other Chloroethyl Agents; 1.3 Platinum-Based Antineoplastic Agents; 1.4 Miscellaneous Alkylating Agents; References; Chapter 2 Antimetabolites; 2.1 Introduction; 2.2 Folate Antagonists; 2.2.1 Compounds with Glutamate Side Chain; 2.2.2 Compounds Lacking the Glutamate Moiety; 2.2.3 Methoxylated Benzenes; 2.3 Pyrimidines and Purines; 2.3.1 Aglycones; 2.3.2 Saccharide-Linked Compounds; References; Chapter 3 Hormone Blocking Anticancer Drugs; 3.1 Introduction 327 $a3.2 Estrogen Antagonists3.2.1 Estrogen Antagonists; 3.2.2 Aromatase Inhibitors; 3.3 Androgen Antagonists; 3.3.1 Non-steroidal Antian drogens; 3.3.2 Steroid Androgen Antagonists; References; Chapter 4 Topoisomerase Inhibitors; 4.1 Introduction; 4.2 Anthracyclines; 4.3 Anthraquinones and Anthrapyrazoles; 4.3.1 Anthraquinones with Two Aminoalkyl Side Chains; 4.3.2 Anthraquinones with a Fused Pyrazole Ring; 4.3.3 Heterocyclic Anthraquinones; 4.4 Camptothecins; 4.4.1 Compounds from Modified Camptothecin; 4.4.2 Camptothecins by Total Synthesis; 4.5 Miscellaneous Topoisomerase Inhibitors; References 327 $aChapter 5 Mitotic Inhibitors5.1 Introduction; 5.2 Taxanes; 5.3 Wholly Synthetic Compounds; 5.3.1 Carbocyclic Compounds; 5.3.2 Peptide-Like Inhibitors; 5.3.3 Monocyclic Heterocyclic Inhibitors; 5.3.4 Bicyclic 5:6 Heterocyclic Inhibitors; 5.3.5 Bicyclic 6:6 Heterocyclic Tubulin Inhibitors; References; Chapter 6 Matrix Metalloproteinase Inhibitors; 6.1 Introduction; 6.2 Hydroxamates; 6.2.1 Agents with an Isobutyl Moiety; 6.2.2 A Thiomorpholine; 6.2.3 Sulfamates; 6.2.4 Miscellaneous Compounds; References; Chapter 7 Histone Deacetylase Inhibitors; 7.1 Introduction; 7.2 Hydroxamates 327 $a7.3 PhenylenediaminesReferences; Chapter 8 Enzyme Inhibitor, Part I, Tyrosine Kinases; 8.1 Introduction; 8.2 Epidermal Growth Factor Inhibitors; 8.3 VEGF; 8.3.1 Fused Ring Compounds; 8.3.2 Linear Arrays; 8.4 SRC Nonreceptor Tyrosine Kinase; 8.5 PDGF; 8.6 EGF; 8.7 Other TKI; 8.7.1 Linear Arrays; 8.7.2 Compounds with Two Fused Rings; 8.8 Janus Kinase Inhibitors; References; Chapter 9 Enzyme Inhibitors: Part II Additional Targets; 9.1 Serine-Threonine Kinase Inhibitors; 9.2 Additional Enzyme Inhibitors; 9.2.1 Farnesyl Transferase Inhibitors; 9.2.2 Cyclin-Dependent Kinase Inhibitors 327 $a9.2.3 Proteasome Inhibitors9.2.4 PARP Inhibitors; 9.2.5 Various Other Enzyme Inhibitors; References; Chapter 10 Miscellaneous Antineoplastic Agents; 10.1 Acyclic; 10.2 Monocyclic; 10.3 Two Linked Rings; 10.4 Rings on a Chain; 10.4.1 Two Rings; 10.4.2 Four and More Rings; 10.5 Fused Rings; 10.5.1 Indoles; 10.5.2 Purine-Like; 10.5.3 Tetralins and a Naphthalene; 10.5.4 Etc.; References; Appendix A; Index of Heterocycle Syntheses; Subject Index; EULA 330 $a"Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations"--$cProvided by publisher. 606 $aAntineoplastic agents 615 0$aAntineoplastic agents. 676 $a616.994061 686 $aSCI007000$2bisacsh 700 $aLednicer$b Daniel$091622 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910131339603321 996 $aAntineoplastic drugs$92279555 997 $aUNINA LEADER 01418aam 2200397I 450 001 9910709910703321 005 20151118015317.0 024 8 $aGOVPUB-C13-58d562c8b7fbab5d214ff62e1a519951 035 $a(CKB)5470000002475164 035 $a(OCoLC)929879260 035 $a(EXLCZ)995470000002475164 100 $a20151118d1979 ua 0 101 0 $aeng 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aCollaborative reference program for color and appearance $eASTM 60 gloss Report no. 2 /$fJ. Horlick; T. L. Cummings 210 1$aGaithersburg, MD :$cU.S. Dept. of Commerce, National Institute of Standards and Technology,$d1979. 215 $a1 online resource 225 1 $aNBSIR ;$v79-1371 300 $a1979. 300 $aContributed record: Metadata reviewed, not verified. Some fields updated by batch processes. 300 $aTitle from PDF title page. 320 $aIncludes bibliographical references. 517 $aCollaborative reference program for color and appearance 700 $aHorlick$b J$01386491 701 $aCummings$b T. L$01386493 701 $aHorlick$b J$01386491 712 02$aUnited States.$bNational Bureau of Standards. 801 0$bNBS 801 1$bNBS 801 2$bGPO 906 $aBOOK 912 $a9910709910703321 996 $aCollaborative reference program for color and appearance$93452872 997 $aUNINA LEADER 03202nam 2200685 a 450 001 9910960396403321 005 20240516003052.0 010 $a9780748698547 010 $a074869854X 010 $a9781845861995 010 $a184586199X 024 7 $a10.1515/9780748698547 035 $a(CKB)2550000001040443 035 $a(EBL)3055056 035 $a(OCoLC)922972158 035 $a(SSID)ssj0001679896 035 $a(PQKBManifestationID)16490088 035 $a(PQKBTitleCode)TC0001679896 035 $a(PQKBWorkID)15023457 035 $a(PQKB)10390179 035 $a(MiAaPQ)EBC3055056 035 $a(Au-PeEL)EBL3055056 035 $a(CaPaEBR)ebr10651505 035 $a(DE-B1597)665695 035 $a(DE-B1597)9780748698547 035 $a(Perlego)1708875 035 $a(EXLCZ)992550000001040443 100 $a20130206d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe student guide to mooting /$fMichael Hammond ; edited by Margaret Ross 205 $a1st ed. 210 $aDundee $cDundee University Press$d2010 215 $a1 online resource (108 p.) 300 $aDescription based upon print version of record. 311 08$a9781845861131 311 08$a1845861132 320 $aIncludes bibliographical references and index. 327 $a""Contents ""; ""Foreword ""; ""Preface ""; ""Chapter 1 introduction to mooting""; ""Chapter 2 counsel""; ""Chapter 3 stage 1: the problem and moot point""; ""Chapter 4 stage 2: making a legal argument""; ""Chapter 5 use of authority""; ""Chapter 6 use of time""; ""Chapter 7 court etiquette""; ""Chapter 8 team tactics and strategies""; ""Chapter 9 body language and presentation skills""; ""Chapter 10 the judge""; ""Chapter 11 procedure on the day of the moot""; ""Chapter 12 advice for the judge""; ""Chapter 13 advice for the clerk""; ""Chapter 14 mooting competitions"" 327 $a""Chapter 15 conclusion""""Further reading ""; ""Appendix 1 mooting example: criminal law""; ""Index of examples""; ""Index of figures""; ""Index"" 330 $aThe ideal introduction to legal argument for new law students and competitive mootersGuiding you through the process of legal argument, this book will teach you all you need to know about how to research and structure your moot, the use of legal authority, honing your presentation skills and addressing the court. To show you how it's done, Hammond provides a worked example applying the two-stage method to creating a legal argument in a moot court. Competitive mooters will find details of internal, national and international competitions and guidelines for event judges and clerks. 606 $aCase method 606 $aMoot courts 606 $aLaw$xStudy and teaching 615 0$aCase method. 615 0$aMoot courts. 615 0$aLaw$xStudy and teaching. 676 $a340.071173 700 $aHammond$b Michael$0174134 701 $aRoss$b Margaret$01813407 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910960396403321 996 $aThe student guide to mooting$94366496 997 $aUNINA